九芝堂：YB211项目启动II期临床试验

Core Viewpoint - The announcement indicates that Jiuzhitang's subsidiary Youbo Pharmaceutical has initiated a Phase II clinical trial for the new drug YB211, which targets acute bacterial skin and skin structure infections caused by Gram-positive pathogens [1] Group 1: Clinical Trial Details - The clinical trial kickoff meeting was held on May 24, 2025, with 26 clinical trial centers, including Fudan University Huashan Hospital [1] - YB211 is a novel cyclic lipopeptide with a new chemical structure, and the trial will compare its efficacy against the control drug Daptomycin in adult patients [1] - The trial consists of two parts: dose exploration and pharmacokinetic studies [1] Group 2: Regulatory Approvals - Youbo Pharmaceutical received the clinical trial approval notice from the National Medical Products Administration on February 6, 2025 [1] - The company obtained the ethics review committee's approval by the end of April [1] Group 3: Impact on Company Performance - The initiation of the clinical trial is expected to advance the research and evaluation progress of the new drug YB211 [1] - However, it is noted that there will be no significant impact on the company's operating performance in the short term [1]